Product Description
TRC150094, a novel mitochondrial modulator, can restore metabolic flexibility by improving insulin resistance in preclinical studies. (Sourced from: https://doi.org/10.3389/fphar.2021.729424)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Torrent
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Dyslipidemia|Hypertension
Phase 2: Insulin Resistance
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01408667 |
CT/P015/CMR/2010/02_01 | P2 |
Completed |
Insulin Resistance |
2012-03-01 |
2019-03-19 |
Treatments |
|
NCT03254446 |
CT/P015/CMR/16/03_01 | P3 |
Unknown status |
Hypertension|Dyslipidemia |
2022-04-01 |
2022-08-03 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|